PEG-Intron peginterferon alfa-2b: Phase III data; under FDA review and marketed in Europe

ENZN and partner Schering-Plough Corp. (SGP, Kenilworth, N.J.) said data from a 48-week international Phase III

Read the full 161 word article

How to gain access

Continue reading with a
two-week free trial.